Work

A phase II randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma (OSCC): Erlo-Xib Study.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.6054

Authors: Sudhir Vasudevan Nair, Amit Joshi, Vijay Maruti Patil, Vanita Noronha, Nilesh Sable, Abhishek Mahajan, Bhasker Dharavath, Nilesh Gardi, Munita Bal, Deepa Nair, Tejpal Gupta, Sarbani Laskar, Jaiprakash Agarwal, Pankaj Chaturvedi, Amit Dutt, Anil D'Cruz, Sudeep Gupta, Kumar Prabhash

Institutions: Tata Memorial Hospital, Advanced Centre for Treatment, Research and Education in Cancer

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947566549

Cites:

Cited by: 10

Related to: 10